AngioDynamics

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products. The company was founded by Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

AngioDynamics reports robust Q2 growth driven by key products

AngioDynamics delivered strong financial results driven by key product growth, reaffirming confidence in guidance and market stability.
Strategic focus on innovation, clinical trials, and global expansion positions the company for long-term success and market leadership.
Challenges in certain business segments require attention, but opportunities in new product releases and market expansion offer growth potential.
Overall, AngioDynamics remains committed to platform technologies and being a trusted care delivery partner, ensuring a strong strategic position in the market.

AngioDynamics reports Q3 growth, navigates challenges, eyes new opportunities

AngioDynamics showed solid revenue growth in Q3 2023, led by the Med Tech segment despite challenges with AngioVac.
The company is focused on addressing sales declines, exploring new product potentials, and maintaining cash flow neutrality.
Opportunities lie in new product usage trends, potential market expansions, and commitment to growth and profitability globally.
Despite revised guidance, AngioDynamics remains resilient in navigating challenges and pursuing strategic opportunities for future growth.

AngioDynamics posts solid earnings, eyes growth through innovation and markets

AngioDynamics delivered strong financial performance in Q4 2023 and FY '23, driven by growth in key segments and international markets.
The company's strategic focus on core businesses and favorable legal outcomes position it for future growth.
Challenges include projected losses for FY '24 and the need to boost Med Device revenue growth.
Opportunities lie in product innovation, clinical study outcomes, and market expansion initiatives.

AngioDynamics reports Q1 growth, eyes innovation amid investor concerns

AngioDynamics' Q1 performance reflects mixed results with revenue growth but losses per share, driven by strong segments like NanoKnife.
The company's financial position remains stable with healthy cash reserves and a positive outlook for future cash flow and revenue growth.
Challenges lie in balancing declining segments like mechanical thrombectomy with growth opportunities in new treatment areas and investor relations.
Opportunities for growth exist through innovation in the Auryon platform, potential indications from the APEX PE study, and strategic investor engagement.
AngioDynamics navigates a complex landscape of growth and challenges, focusing on innovation and financial stability amidst investor concerns.

AngioDynamics reports Q2 growth, navigates challenges with strategic initiatives

AngioDynamics delivered steady revenue growth in Q2 2024, driven by international expansion and strong performance in key segments.
While facing challenges in certain businesses, the company is strategically restructuring operations and investing in innovation for future growth.
Opportunities lie in expanding Auryon's market reach, optimizing manufacturing processes, and maintaining a focus on cost efficiency.
Overall, AngioDynamics is navigating challenges while positioning itself for long-term success through strategic initiatives and product enhancements.

AngioDynamics reports strong Q3 growth, eyes global expansion opportunities

AngioDynamics demonstrated solid revenue growth and strategic milestones in Q3 2024, with a focus on product innovation and international expansion.
While facing challenges in certain business segments, the company's regulatory successes and financial stability position it well for future growth.
Opportunities in upcoming data releases and market trends present avenues for AngioDynamics to capitalize on its strengths and drive further success.

AngioDynamics reports Q4 growth, eyes revenue expansion in 2025

AngioDynamics delivered a mixed performance in Q4 2024 with growth in Med Tech segment but declines in mechanical thrombectomy and Med Device segments.
Despite challenges, the company managed to generate excess cash flow and narrow its adjusted EBITDA loss, showcasing financial resilience.
Future opportunities lie in revenue growth projections for fiscal year 2025 and strategic initiatives aimed at market expansion and optimization.

AngioDynamics reports modest revenue growth and progresses towards profitability

AngioDynamics demonstrated overall growth in revenue and progress towards profitability in Q1 2025. While facing challenges with NanoKnife revenue and profitability, the company's Med Tech segment showed strength with Auryon and AlphaVac. Opportunities lie in cost savings from outsourced manufacturing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to.

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.

AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors

In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.

Why AngioDynamics (ANGO) Dipped More Than Broader Market Today

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Virtual Healt.

AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

Aurora Cannabis

APA Corporation

BioNTech SE

Franco-Nevada C

Gilead Sciences

Xcel Energy

Ordinarily, you'll want to avoid excessively red-stained ideas. Although certain exceptions might be made for these oversold stocks ready for rebound.

Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound

In the most recent trading session, AngioDynamics (ANGO) closed at $5.99, indicating a +1.7% shift from the previous trading day.

Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today

AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.

AngioDynamics (ANGO) Divests Its PICC & Midline Businesses

AngioDynamics (ANGO) closed at $6.17 in the latest trading session, marking a +1.31% move from the prior day.

Why AngioDynamics (ANGO) Outpaced the Stock Market Today

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has completed the sale of its PICC and Midline product portfolios to Spectrum Vascular, an innovative medical device company focused on vascular access and medication management, for up to $45 million in cas.

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

The latest trading day saw AngioDynamics (ANGO) settling at $6.09, representing a -0.98% change from its previous close.

AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why

AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.

AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disea.

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in second-quarter fiscal 2024.

AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss

The adjusted losses that the medical device maker reported for its fiscal Q2 weren't as bad as expected, but its sales weren't as good as expected. The Nanoknife-maker has lost money for five straight years.

Why AngioDynamics Stock Got Destroyed Today

AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript

AngioDynamics (ANGO) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.01 per share a year ago.

AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates

Shares of AngioDynamics Inc. ANGO, +0.26% plummeted 16.8% in premarket trading, after the medical devices company widened its full-year loss forecast and announced a restructuring of its manufacturing footprint. Net losses for the fiscal second quarter to Nov. 30 widened to $29.05 million, or 72 cents a share, from $8.49 million, or 21 cents a share, in the year-ago period.

AngioDynamics stock dives after sales miss, lowered full-year outlook

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2024, which ended November 30, 2023. “Today, we are announcing meaningful steps in our strategic transformation. We have initiated a restructuring of our.

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00 a.

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day.

AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same.

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company's Alph.

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

AngioDynamics (ANGO) closed the most recent trading day at $6.77, moving -1.31% from the previous trading session.

AngioDynamics (ANGO) Falls More Steeply Than Broader Market: What Investors Need to Know

In the most recent trading session, AngioDynamics (ANGO) closed at $6.74, indicating a -0.15% shift from the previous trading day.

News for AngioDynamics Stock (ANGO)